Join our community of smart investors

Verona suffers clinical trial failure

The drug developer's potential new respiratory drug failed to meet initial targets in a second-phase trial
Verona suffers clinical trial failure

A clinical failure from Verona Pharma (VRP) sent shares in the drug developer crashing further. A three-day second-phase trial – of a potential respiratory drug known as RPL554 – saw it administered to patients on top of an inhaler commonly used in the treatment of chronic obstructive pulmonary disease (COPD).

IC TIP: Hold at 80p

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in